RLYB

Rallybio Corp (RLYB) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. Rallybio Corp is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases. The company's lead program, RLYB116, is a C5 inhibitor for complement dysregulation diseases. A secondary program, RLYB332, targets iron overload. The company reported positive data from a confirmatory Phase 1 PK/PD study of RLYB116 in Q1 2026. Notably, the company discontinued its RLYB212 program in April 2025 due to insufficient pharmacokinetic data.

Key Financial Metrics

Note: Cash and marketable securities increased significantly due to proceeds from the maturity of marketable securities ($17.9 million) and a subsequent event (see below).

Material Changes vs. Prior Period

• Net Loss Improvement: Net loss decreased by $1.2 million (12%) compared to Q1 2025, primarily driven by a reduction in Research and Development (R&D) expenses.
• R&D Expenses: Decreased by $2.9 million to $2.9 million. This was largely due to the discontinuation of the RLYB212 program (saving $2.4 million) and reduced manufacturing costs for RLYB116.
• G&A Expenses: Increased by $1.9 million to $6.1 million. This increase was primarily driven by legal and professional fees associated with a terminated merger agreement with Candid Therapeutics, Inc., partially offset by lower personnel costs.
• Joint Venture Loss: The company recorded no loss on its investment in a joint venture in Q1 2026, compared to a $0.6 million loss in Q1 2025, following the sale of its interest in REV102 to Recursion Pharmaceuticals in July 2025.
• Severance Charges: The company incurred approximately $2.3 million in severance charges in Q1 2026 related to the terminated merger, included in R&D and G&A expenses.

Guidance, Outlook, and Subsequent Events

• Terminated Merger & Termination Fee: On May 3, 2026, the proposed merger with Candid Therapeutics was terminated. As a result, Rallybio received a $50.0 million Parent Termination Fee and $0.4 million in expense reimbursements on May 4, 2026. This is a significant subsequent event not reflected in the Q1 2026 balance sheet.
• Liquidity: As of March 31, 2026, the company held $46.8 million in cash and marketable securities. Management expects these funds to be sufficient for operations for at least 12 months. However, the company anticipates needing substantial additional capital to complete product development and commercialization.
• Outlook: The company remains focused on advancing RLYB116. It does not expect to achieve profitability in the foreseeable future and will continue to incur losses as it progresses clinical development.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional financing which may cause dilution, and reliance on third-party manufacturers and CROs.

Investor Verification Checklist

• Termination Fee Impact: Verify the accounting treatment and timing of the $50.0 million termination fee received in May 2026 and its impact on the company's runway.
• RLYB116 Clinical Progress: Confirm the timeline and design for the next phase of clinical trials for RLYB116 following the successful Phase 1 PK/PD data.
• Capital Requirements: Assess the company's specific capital needs to reach the next major milestone and the potential dilution from future equity raises.
• Severance Obligations: Review the remaining accrued severance liability ($1.4 million as of March 31, 2026) and expected cash outflows.
• Revenue Sustainability: Note that the $212k revenue recognized in Q1 2026 was from a collaboration agreement with Johnson & Johnson that terminated in April 2026; future revenue streams are not yet established.